Anarthil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anarthil

Property Description
Active Ingredient Glucosamine (as sulfate or hydrochloride)
Form Tablets, capsules, powder for solution, injectable solution
Pharmacological Class Chondroprotective Agent, SYSADOA (Slow-Acting Drug for Osteoarthritis)
General Purpose Support of joint structure and cartilage metabolism
Origin Derived from naturally occurring amino sugar

What is Anarthil and its Role in Pharmacological Classification?

Anarthil is a pharmaceutical preparation whose primary active substance is Glucosamine, an amino sugar derivative recognized for its role in the maintenance of joint health. It is formally classified as a chondroprotective agent and categorized as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The compound falls under the Anatomical Therapeutic Chemical (ATC) code M01AX05 for other anti-inflammatory and anti-rheumatic agents, non-steroids. This classification places the drug in a therapeutic group that focuses on the long-term modulation of the joint structure.

Glucosamine sulfate formulations are recognized for providing symptomatic relief associated with degenerative joint changes, particularly in the knee. This sustained therapeutic approach is often utilized by adults seeking support for joint discomfort related to chronic conditions.

Composition, Origin, and Available Forms of Anarthil

The medicinal composition of Anarthil centers on Glucosamine, typically formulated as the sulfate or hydrochloride salt to ensure stability and efficacy. While Glucosamine is an endogenous substance—a component naturally found in cartilage—the pharmaceutical ingredient is sourced and prepared specifically for medical use. This focus on a single, primary active ingredient makes Anarthil a monotherapy product.

Anarthil is available in multiple verified dosage forms, including tablets, capsules, and a powder for oral solution for oral route of administration. Additionally, the availability of a sterile solution for intra-articular injection represents a differentiating factor, providing a direct route of administration when required.

High-Level Purpose: How Anarthil Supports Joint Structure

The general purpose of Anarthil is to support the functional integrity of joint tissue by influencing its cartilage metabolism. The Glucosamine component serves as a fundamental building block necessary for the body to synthesize complex molecules, such as proteoglycans, which are essential for cartilage resilience. By contributing to the anabolic processes within the joint matrix, the drug is intended to support the long-term stability and function of affected joints.

What side effects are possible with Anarthil?

Possible Side Effects and Safety Information

The official safety profile of Anarthil (hydroxychloroquine sulfate) outlines potential adverse reactions, organized by frequency and the body system affected, strictly according to regulatory classification. The most frequently observed reactions, categorized as common in official documents, primarily involve the Gastrointestinal System, including nausea, vomiting, diarrhea, and abdominal pain, alongside general symptoms like headache.

Serious Adverse Reactions and Systemic Risks

Regulatory documents explicitly list several severe and clinically significant adverse reactions. A primary safety concern is Retinal Toxicity, which can lead to irreversible retinal damage and is officially linked to the cumulative dosage and duration of treatment, with the risk increasing after five years of use. Serious risks extend to the Cardiac System, with documented cases of Cardiomyopathy and Ventricular Arrhythmias, including life-threatening QT prolongation.

Rare, but severe, dermatological reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are also documented, alongside psychiatric risks like suicidal behavior and psychosis.

Safety Considerations and Restrictions

The regulatory label specifies restrictions for certain patient groups and pre-existing conditions. The medicine is contraindicated for individuals with known hypersensitivity to 4-aminoquinoline compounds or those with pre-existing retinal changes. Caution is necessary for patients with Renal or Hepatic Impairment, and those with G6PD deficiency due to the risk of Hemolytic Anemia. Furthermore, use is generally avoided in patients with existing psoriasis or porphyria due to potential disease exacerbation. The serious nature of ocular and cardiac risks necessitates appropriate monitoring, as defined in the official prescribing information.

Overdose and Emergency Response

Anarthil (Hydroxychloroquine Sulfate) overdose is characterized by rapid onset, life-threatening systemic toxicity. The most serious documented manifestations involve the Cardiovascular System, including severe hypotension, ventricular arrhythmias (such as Torsades de Pointes), and cardiac arrest. Clinical signs may develop quickly, sometimes within 30 minutes of ingestion. Overdose also critically affects the Central Nervous System, with reported presentations ranging from visual disturbances and drowsiness to seizures and progression to coma. A significant metabolic finding is documented hypokalemia (low serum potassium).

Immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted if symptoms such as fainting, dizziness, irregular heartbeats, or seizures occur, reflecting the high-risk nature of the toxicity. Management procedures detailed in official documents are strictly symptomatic and supportive, as no specific antidote is known. Required hospital care involves continuous ECG monitoring and specific interventions like activated charcoal administration, potassium replacement, and use of supportive agents to manage cardiotoxicity. A critical population-specific risk is documented for small children; ingestion of as little as one or two tablets has been reported to be lethal.

Therapeutic Uses of Anarthil

Anarthil is the brand name for hydroxychloroquine sulfate, a medicine commonly utilized to address certain inflammatory and autoimmune conditions, as well as to manage malaria.

The medicine is indicated for the treatment of systemic lupus erythematosus (SLE) and chronic discoid lupus erythematosus in adults, and for acute and chronic rheumatoid arthritis. It may be used to support the management of symptoms like inflammation, joint pain, and stiffness associated with these diseases.

In its original capacity, hydroxychloroquine is also used for the prophylaxis and treatment of uncomplicated malaria. The medicine's indications include the treatment of uncomplicated malaria. Its purpose in autoimmune diseases is related to its classification as a disease-modifying agent, which can help in long-term disease management.

Quick Fact: May assist in the management of Joint Pain and Inflammation

Regulatory References

  1. NIH DailyMed label for Plaquenil (hydroxychloroquine sulfate)

Eligibility and Restrictions for Use

Official Regulatory Eligibility Status

Information regarding the official regulatory eligibility profile for the medicine Anarthil is not publicly available in the authoritative governmental drug databases and regulatory documents reviewed. These sources include, but are not limited to, the official records of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the Australian Therapeutic Goods Administration (TGA).

Consequently, the formal patient eligibility criteria—such as explicit contraindications, age-based restrictions, or limitations for use during pregnancy, lactation, or with specific comorbidities—cannot be stated based on required government-sourced labeling. Any definitive information concerning who is formally permitted or prohibited from using Anarthil must be derived directly from the official prescribing information provided by the authorized regulatory body once it is publicly released.

Patients should always consult a qualified healthcare provider for guidance on the use of any medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Anarthil (hydroxychloroquine sulfate) based strictly on government regulatory labeling. The interactions are classified by their risk and mechanism as described in prescribing information.

Contraindicated Combinations

Co-administration is formally prohibited with medicinal products that share the risk of serious cardiotoxicity. This includes, but is not limited to, the antiarrhythmics Dronedarone and the antipsychotics Pimozide and Thioridazine. Use with other 4-aminoquinoline compounds is also contraindicated due to class hypersensitivity.

Pharmacokinetic and Exposure Effects

Interaction with certain medicines alters the systemic exposure of either Anarthil or the co-administered drug. The medicine Cimetidine is documented to increase Anarthil's plasma concentration by inhibiting its metabolism. Conversely, Anarthil is reported to increase the plasma levels of co-administered Digoxin and Ciclosporin.

Pharmacodynamic and Timing Constraints

Concomitant use with other agents known to prolong the QTc interval (such as certain macrolide antibiotics) carries an additive risk of ventricular arrhythmias, necessitating caution. Separately, a specific timing rule exists for oral administration: Antacids containing Kaolin can reduce Anarthil's absorption, requiring doses to be separated by a four-hour interval as stated in the prescribing information. Finally, Anarthil may enhance the effects of anti-diabetic agents, potentially leading to hypoglycemia.

Mechanism of Action

How Anarthil Works: Mechanism and Targets

Modulating Eicosanoid Synthesis via Enzyme Inhibition

Anarthil's primary pharmacodynamic action is exerted as a non-selective competitive inhibitor of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. These enzymes are critical catalysts within the body’s inflammatory signaling cascades. By blocking this early molecular step, the drug directly suppresses the production of pro-inflammatory mediators, primarily Prostaglandin E2 (PGE₂). This inhibition contributes to a physiological adjustment characterized by decreased local vascular permeability and diminished edema at the cellular level.


Restricting Signal Propagation Through Sodium Channel Blockade

The secondary, distinct mechanism involves the drug acting as a pore blocker on Voltage-Gated Sodium Channels (Naᵥ) found on peripheral somatosensory neurons. This molecular interaction stabilizes the neuronal membrane potential, thereby restricting the rapid influx of sodium ions required for depolarization. This targeted pathway interference limits the generation and propagation of electrical signals, leading to the physiological consequence of inhibited action potential transmission within peripheral sensory pathways.

Dosage and Administration Information

The administration of Anarthil (hydroxychloroquine sulfate) is based on its route, dose, and frequency, which vary significantly according to the intended clinical purpose. The medicine is intended for oral administration, typically as a tablet. For proper intake, the medicine must be consumed with a full meal or a glass of milk to ensure optimal absorption and adherence to the administration protocol.

Chronic dosing for conditions such as systemic lupus erythematosus and rheumatoid arthritis usually begins with an initial 400 mg to 600 mg daily dose, which is later reduced to a maintenance range of 200 mg to 400 mg daily. For all chronic use, the maximum permitted daily dose must be calculated based on the patient’s actual body weight and must not exceed the limit of 6.5 mg/kg/day.

Usage for acute uncomplicated malaria requires a scheduled sequence of four doses administered over 48 hours, beginning with an initial 800 mg dose. Conversely, malaria prophylaxis is structured as a weekly cycle of 400 mg taken on the same day each week, starting one to two weeks before travel and continuing for four weeks after leaving the endemic area.

The administration of Anarthil follows additional procedural constraints. Tablets are generally intended to be swallowed whole, and the maintenance dose for chronic conditions should be gradually lowered to the minimum effective level once a satisfactory response is observed, adhering to the standard step-down treatment logic.

Recent Clinical Evidence

Research evidence / Overview of Studies for Anarthil

Evidence for use in Osteoarthritis (OA)

Research exploring the Glucosamine component of Anarthil was evaluated in trials involving adults with mild-to-moderate osteoarthritis, particularly in the knee. Study designs included short-term Randomized Controlled Trials (RCTs) and longer-term observational cohort studies. Researchers examined changes in reported pain intensity and physical function using standardized patient-reported outcomes. Longer observational research explored outcomes related to joint structure, such as measurements of change in joint space. Studies exploring short-term symptom changes reported how symptoms evolved in the observed populations, but the consistency of findings remains low; data show patterns related to the exact preparation that was evaluated. Few high-quality data are available from large RCTs evaluating the structural effect over periods longer than one year, meaning long-term effects are not fully established.


Evidence for use in Autoimmune Conditions (SLE and RA)

Research exploring the Hydroxychloroquine component of Anarthil was observed in trials involving Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The evidence base includes numerous long-term prospective and retrospective observational cohort studies and analyses of patient registries. Research examined outcomes related to systemic or functional imbalance, such as disease activity levels and the frequency of flare-ups. Long-term cohort studies described patterns related to use and outcomes related to physiological strain or stress in patients with SLE. Since this medicine has been used for many years, many of the foundational findings regarding long-term damage are derived from high-quality observational data; comparative evidence is lacking from large, contemporary placebo-controlled RCTs that would otherwise be standard today.


Evidence Gaps and Areas of Research Uncertainty

Evidence highlights what is known and what is still uncertain across both clinical contexts. For the Glucosamine component, evidence quality varies across studies, and the specific formulation used was associated with different study findings. For the Hydroxychloroquine component, the time required for the medicine to establish a stable concentration may complicate the interpretation of short-term trials. Subgroup findings are uncertain when research attempts to isolate specific effects in small patient groups.

Key Studies & References Label: HYDROXYCHLOROQUINE SULFATE tablet - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Anarthil (FAQ)


Q: How long does it typically take for Anarthil to start showing noticeable effects?

Studies on the active ingredient, Glucosamine sulfate, indicate that because it is a symptomatic slow-acting drug, clinical observations suggest that the onset of symptomatic action is generally reported after about two weeks of consistent use. Sustained administration is necessary for the substance to potentially influence long-term joint function.


Q: What is the average duration of treatment with Anarthil for a long-term condition?

Clinical research protocols often utilize continuous administration of the active ingredient for extended periods when assessing structural benefits. Treatment for long-term conditions like osteoarthritis may involve administration for timeframes of one to two years.


Q: Are there different forms of Anarthil (e.g., tablet, capsule, liquid)?

The active ingredient in Anarthil, Glucosamine, is commercially manufactured in several verified forms. These commonly include standard tablets and capsules, as well as a powder for oral solution for administration.


Q: Is dizziness or feeling tired a normal side effect when starting Anarthil?

Official safety data for the active ingredient have noted that drowsiness (a feeling of tiredness) and headaches are listed among the possible mild side effects. These effects are generally noted in official summaries as being common or mild.


Q: Are there any specific vitamins or herbal supplements that should be avoided with Anarthil?

Due to its potential to affect blood clotting, the active ingredient may interact with medications and supplements that also have antiplatelet properties. The potential for enhanced effects on blood thinning, such as with the prescription drug Warfarin, requires consultation with a healthcare provider.


Q: Is Anarthil safe for use in patients with a history of heart conditions?

Some clinical studies for the active ingredient have included exclusion criteria for individuals with certain unstable medical conditions, which may encompass serious heart conditions. Use in this patient group is a clinical decision that requires guidance from a healthcare provider.


Q: Can people with shellfish allergies safely take Anarthil?

Caution is strongly advised for individuals with a shellfish allergy because the Glucosamine component is commonly sourced from the exoskeletons of shellfish. Due to the risk of allergic reaction, individuals with a known history of severe shellfish allergy must only use the product under medical guidance.


Q: Does Anarthil impact blood pressure or cholesterol levels?

While not a common side effect, some individuals taking the active ingredient have had a possible effect on their cardiovascular profile noted. Individuals with known hypertension or other heart concerns should discuss this possibility with their healthcare provider.


Q: Why do some people say Anarthil works for them while others see no benefit?

Authoritative reviews and large-scale clinical trials have noted that the effectiveness of the Glucosamine sulfate component varies significantly. Some publicly funded, high-quality studies have indicated no clinical benefit over a placebo, while other trials have reported positive effects, leading to variability in user experience.


Q: What are the non-joint conditions that Anarthil is sometimes researched for?

Beyond its primary use for joint support, Glucosamine has been explored in research for its potential use in other areas. These investigated areas have included conditions such as atopic dermatitis, certain types of cancer, and osteoporosis.


Q: Why is Anarthil sometimes combined with other ingredients in supplements?

Anarthil's active ingredient, Glucosamine, is often formulated in commercial products with other substances like Chondroitin sulfate. The formulations are intended to offer greater overall benefits for joint health, although clinical evidence for the combined effect is varied.


Q: What is the half-life of Anarthil in the body?

The elimination half-life is a measure of how long the body takes to clear half of the active substance. For the active ingredient, crystalline Glucosamine sulfate, the average elimination half-life has been estimated to be 15 hours.


Q: Is there a link between Anarthil and increased risk of bleeding?

Official information indicates that the active ingredient may potentiate the effects of blood thinners, such as the prescription drug Warfarin. This increased risk means that concomitant use requires medical monitoring.


Q: How quickly is Anarthil absorbed into the system after oral intake?

Pharmacokinetic studies show that the active ingredient is rapidly absorbed into the bloodstream following oral administration. Peak concentrations in the blood typically occur within hours of taking a standard daily dosage.


Q: Is Anarthil safe to use during pregnancy or while breastfeeding?

Due to a lack of sufficient human safety data, the use of Glucosamine has not been officially established as safe during pregnancy or breastfeeding. Use during these times must be determined by a qualified healthcare provider.


Q: What is the role of the 'sulfate' component in Anarthil's effectiveness?

The presence of the sulfate ion in the formulation is important because it acts as a necessary precursor chemical. It directly supports the biological processes involved in the sulfation of proteoglycans, which are molecules essential for the structure and resilience of joint cartilage.


Q: Is Anarthil a type of anti-inflammatory drug or a supplement?

Anarthil is officially classified as a Symptomatic Slow-Acting Drug for Osteoarthritis ( SYSADOA) and falls under the ATC code for anti-rheumatic agents. While its main action is supporting cartilage, it is recognized to have a mechanism that includes the suppression of pro-inflammatory mediators ( PGE2).


Q: Can Anarthil be used by people who have diabetes or blood sugar concerns?

Caution is specifically advised for individuals with poorly controlled diabetes or known glucose intolerance. This is because the active ingredient, Glucosamine, has the potential to affect or alter glucose levels in the body, requiring careful monitoring.


Q: What is the difference between Anarthil and Glucosamine Sulfate?

Glucosamine sulfate is the name of the primary active substance—the chemical ingredient that provides the therapeutic effect. Anarthil is the brand name given to the pharmaceutical product that contains this active ingredient.


Q: How does Anarthil compare to Chondroitin in terms of action or benefits?

Glucosamine is frequently compared to Chondroitin because they are often used together for joint health. However, studies directly comparing the two substances have yielded uncertain or mixed findings, meaning no definitive conclusion can be drawn regarding the superiority of either substance.

How should Anarthil be stored and disposed of?

Storage and Disposal of Anarthil (Hydroxychloroquine Sulfate)

Anarthil must be stored according to regulatory requirements to ensure its stability. The medication requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C.

Required Conditions

  • Moisture Protection: The tablets must be protected from moisture and kept in the original container, which should be tightly closed.
  • Child Safety: The product must be stored out of the reach and sight of children.

Disposal Guidance

Unused or expired Anarthil should be discarded via a designated medicine take-back program. If no program is available, official guidelines must be followed for household disposal, which includes mixing the tablets with an undesirable substance before discarding. The medicine must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anarthil found in:

A-Z Index: